Sunaina Nayak
0009-0003-2736-3100
Publication & Citation Trends
Publications
0 total
DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers.
Cited by 0
Semantic Scholar
Abstract A031: DHX9 inhibition induces genomic instability and enhances paclitaxel sensitivity in drug-resistant high-grade serous ovarian cancer (HGSOC) cells
Cited by 0
Semantic Scholar
Abstract B045: ATX-559, a first-in-class, clinical-stage DHX9 inhibitor, as a targeted therapeutic for molecularly defined tumors with genomic instability and replicative stress
Cited by 0
Semantic Scholar
Abstract 1758: ATX-559, a first in class DHX9 inhibitor, and targeted therapeutic for molecularly defined tumors with genomic instability and replicative stress
Cited by 0
Semantic Scholar
Abstract PR006: Target validation and drug discovery efforts on exoribonuclease XRN1
Cited by 0
Semantic Scholar
A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair
Cited by 8
Semantic Scholar
Abstract 3908: DHX9 inhibition as a novel therapeutic for cancer with loss-of-function mutations in DNA damage repair genes BRCA1 and BRCA2
Cited by 0
Semantic Scholar
Abstract A163: Exoribonuclease XRN1 is a therapeutic vulnerability in tumors with intrinsically elevated type I interferon signaling
Cited by 0
Semantic Scholar
Abstract 3260: Potentiation of Type I interferon signaling leads to in vivo efficacy achieved with combination of chemotherapy and the PARP7 inhibitor RBN-2397
Cited by 0
Semantic Scholar
Wearable Safety Device for Children OA
Cited by 3
Semantic Scholar
Research Topics
Science, Research, and Medicine
(20)
Biotechnology and Related Fields
(13)
RNA and protein synthesis mechanisms
(11)
RNA Research and Splicing
(11)
Steroid Chemistry and Biochemistry
(11)
Affiliations
Harvard University
Akebia Therapeutics (United States)
Accent Therapeutics (United States)
Ribon Therapeutics (United States)